Fig. 4

ETS-1 is involved in cisplatin resistance in HNSCC. a. Cal27 and Cal27CP cells were treated with increasing doses of cisplatin for 24 h, lysed, and analyzed for caspase-3 cleavage by Western blot with β-Actin as loading control. b and d. Cal27CP (B) and UMSCC74B (d) cells were transfected with non-target siRNA or siRNA against ETS-1 for 24 h, treated with increasing doses of cisplatin for 24 h, and the expression of the indicated proteins was detected by Western blot. C and E. Cal27CP (c) and UMSCC74B (e) cells were transfected with non-target siRNA or siRNA against ETS-1 for 24 h, seeded into 6-well plates for 24 h, then treated with increasing doses of cisplatin for 72 h. Cell proliferation was measured by MTS assay